

**UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF COLUMBIA**

---

JANE DOE 2, JANE DOE 3, JANE DOE 4,  
JANE DOE 5, JANE DOE 6, JANE DOE 7,  
JOHN DOE 1, JOHN DOE 2, REGAN V.  
KIBBY, and DYLAN KOHERE,

Plaintiffs,

v.

DONALD J. TRUMP, in his official capacity as  
President of the United States; JAMES N.  
MATTIS, in his official capacity as Secretary of  
Defense; JOSEPH F. DUNFORD, JR., in his  
official capacity as Chairman of the Joint Chiefs  
of Staff; the UNITED STATES  
DEPARTMENT OF THE ARMY; MARK T.  
ESPER, in his official capacity as Secretary of  
the Army; the UNITED STATES  
DEPARTMENT OF THE NAVY; RICHARD  
V. SPENCER, in his official capacity as  
Secretary of the Navy; the UNITED STATES  
DEPARTMENT OF THE AIR FORCE;  
HEATHER A. WILSON, in her official  
capacity as Secretary of the Air Force; the  
UNITED STATES COAST GUARD;  
KIRSTJEN M. NIELSEN, in her official  
capacity as Secretary of Homeland Security; the  
DEFENSE HEALTH AGENCY; RAQUEL C.  
BONO, in her official capacity as Director of  
the Defense Health Agency; and the UNITED  
STATES OF AMERICA,

Defendants.

---

Civil Action No. 17-cv-1597 (CKK)

**ERRATA**

Plaintiffs’ counsel inadvertently included the wrong title for Exhibit SS to the Declaration of Lauren Godles Milgroom (ECF No. 128-45). For the Court’s convenience, Plaintiffs have submitted a corrected version of Exhibit SS as an attachment to this errata.

May 14, 2018

Claire Laporte (*pro hac vice*)  
Matthew E. Miller (*pro hac vice*)  
Daniel McFadden (*pro hac vice*)  
Kathleen M. Brill (*pro hac vice*)  
Michael Licker (*pro hac vice*)  
Rachel C. Hutchinson (*pro hac vice*)  
Lauren Godles Milgroom (*pro hac vice*)  
FOLEY HOAG LLP  
155 Seaport Blvd.  
Boston, Massachusetts 02210  
Telephone: 617-832-1000  
Fax: 617-832-7000

Theresa M. Roosevelt (D.C. Bar No. 1021853)  
FOLEY HOAG LLP  
1717 K Street NW  
Washington, DC 20006  
Telephone: 202-223-1200  
Fax: 202-785-6687

Jennifer Levi (*pro hac vice*)  
Mary L. Bonauto (*pro hac vice*)  
GLBTQ LEGAL ADVOCATES & DEFENDERS  
18 Tremont St., Ste. 950  
Boston, Massachusetts 02108  
Telephone: 617-426-1350  
Fax: 617-426-3594

Shannon P. Minter (*pro hac vice*)  
Amy Whelan (*pro hac vice*)  
Chris Stoll (*pro hac vice*)  
NATIONAL CENTER FOR LESBIAN RIGHTS  
870 Market St., Ste. 370  
San Francisco, California 94102  
Telephone: 415-392-6257  
Fax: 415-392-8442

Respectfully submitted,

/s/ Alan E. Schoenfeld  
Paul R.Q. Wolfson (D.C. Bar No. 414759)  
Kevin M. Lamb (D.C. Bar No. 1030783)  
WILMER CUTLER PICKERING  
HALE & DORR LLP  
1875 Pennsylvania Ave. N.W.  
Washington, D.C. 20006  
Telephone: 202-663-6000  
Fax: 202-663-6363

Alan E. Schoenfeld (*pro hac vice*)  
WILMER CUTLER PICKERING  
HALE & DORR LLP  
7 World Trade Center  
250 Greenwich St.  
New York, New York 10007  
Telephone: 212-230-8800  
Fax: 212-230-8888

Christopher R. Looney (*pro hac vice*)  
Harriet Hoder (*pro hac vice*)  
Adam M. Cambier (*pro hac vice*)  
WILMER CUTLER PICKERING  
HALE & DORR LLP  
60 State Street  
Boston, Massachusetts 02109  
Telephone: 617-526-6000  
Fax: 617-526-5000

Nancy Lynn Schroeder (*pro hac vice*)  
WILMER CUTLER PICKERING  
HALE & DORR LLP  
350 S. Grand Ave., Ste. 2100  
Los Angeles, California 90071  
Telephone: 213-443-5300  
Fax: 213-443-5400

*Attorneys for Plaintiffs*

**IN THE UNITED STATES DISTRICT COURT FOR  
THE DISTRICT OF COLUMBIA**

_____	)	
DOE, et al.,	)	
	)	
<i>Plaintiffs,</i>	)	
	)	
v.	)	Civil Action No. 17-cv-1597 (CKK)
	)	
DONALD TRUMP, et al.,	)	
	)	
<i>Defendants.</i>	)	
_____	)	

**DECLARATION OF JOSHUA D. SAFER, MD, FACP  
IN SUPPORT OF PLAINTIFFS’ OPPOSITION TO DEFENDANTS’ MOTION TO  
DISSOLVE THE PRELIMINARY INJUNCTION**

I, Joshua D. Safer, declare as follows:

1. I make this declaration based on my own personal knowledge.

**PROFESSIONAL BACKGROUND**

2. I am a Staff Physician in the Department of Medicine at the Mount Sinai Hospital and Mount Sinai Beth Israel Medical Center in New York, NY. I serve as Executive Director of the Center for Transgender Medicine and Surgery at Mount Sinai. I also hold an academic appointment as Senior Faculty in Mount Sinai’s Icahn School of Medicine. A true and correct copy of my CV is attached hereto as Exhibit A.

3. I am Board Certified in Endocrinology, Diabetes and Metabolism by the American Board of Internal Medicine, and I have been since 1997.

4. I graduated from the University of Wisconsin in Madison with a Bachelor of Science in 1986. I earned my Doctor of Medicine degree from the University of Wisconsin in 1990. I completed intern and resident training at Mount Sinai School of Medicine, Beth Israel Medical

Center in New York, New York from 1990 to 1993. From 1993 to 1994, I was a Clinical Fellow in Endocrinology at Harvard Medical School and Beth Israel Deaconess Medical Center in Boston, Massachusetts. I stayed at the same institution, serving as a Clinical and Research Fellow in Endocrinology under Fredric Wondisford, from 1994 to 1996.

5. Since 1997, I have evaluated and treated patients along with conducting research in endocrinology. Since 2004, the patient care and research has been the medicine/science specific to transgender individuals. I have led several other programs either in transgender medicine or in general endocrinology. In particular, I served as Medical Director of the Center for Transgender Medicine and Surgery, Boston Medical Center, Boston, MA (2016-2018); as Director of the Medical Education, Endocrinology Section, Boston University School of Medicine, Boston, MA (2007-2018); as Program Director of the Endocrinology Fellowship Training, Boston University Medical Center, Boston, MA (2007-2018); and as Director of the Thyroid Clinic, Boston Medical Center, Boston, MA (1999-2003).

6. I have authored or coauthored 71 papers in peer-reviewed journals, including many critical reviews; textbook chapters; and case reports in endocrinology and transgender medicine.

7. I have served as a Transgender Medicine Guidelines Drafting Group Member for the International Olympic Committee (“IOC”) since 2017.

8. I currently serve as the President of the United States Professional Association for Transgender Health (USPATH). I am also Secretary and Co-Chair of the Steering Committee of TransNet, the International Consortium for Transgender Medicine and Health Research. I have served in several other leadership roles in professional societies related to endocrinology and transgender health. These societies include the Alliance of Academic Internal Medicine, the American College of Physicians Council of Subspecialty Societies, the American Board of

Internal Medicine, the Association of Program Directors in Endocrinology and Metabolism, and the American Thyroid Association.

9. Since 2014, I have held various roles as a member of the World Professional Association for Transgender Health (“WPATH”), the leading international organization focused on transgender health care. WPATH has over 1,000 members throughout the world and is comprised of physicians, psychiatrists, psychologists, social workers, surgeons, and other health professionals who specialize in the diagnosis and treatment of transgender individuals. From 2016 to the present I have served on the Writing Committee for Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People.

10. I have served in various roles as a member of the Endocrine Society since 2014. I served as a Task Force member to develop the Endocrine Treatment of Transgender Persons Clinical Practice Guideline from 2014 to 2017. As part of this task force of nine experts, a methodologist, and a medical writer, I contributed to the “Endocrine Treatment of Gender-Dysphoria/Gender Incongruent Persons: An Endocrine Society Clinical Practice Guideline,” (“Endocrine Society Guidelines”).<sup>1</sup> These were an update to the “Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline,” published by the Endocrine Society in 2009.

11. I served in the Wisconsin Army Reserve National Guard from 1987 to 1990 and remained in the Army Reserve until 1995. This service made me sympathetic to the unique needs of servicemembers and reflected my support for the military as an institution. Since then, I

---

<sup>1</sup> Wylie C. Hembree, Peggy T. Cohen-Kettenis, Lous Gooren, Sabine E. Hannema, Walter J. Meyer, M. Hassan Murad, Stephen M. Rosenthal, Joshua D. Safer, Vin Tangpricha & Guy T’Sjoen, “Endocrine Treatment of Gender-Dysphoria/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline,” *The Journal of Clinical Endocrinology & Metabolism*, Vol. 102, pp. 3869-3903 (Nov. 2017).

have continued to devote a significant part of my career to assisting people in the military and veterans, including from 2001 to 2006 when I served as a Staff Physician at the Veterans Administration Boston Health Care System in Boston, Massachusetts.

**CONSULTING FOR THE DEPARTMENT OF DEFENSE WORKING GROUP BEFORE  
RELEASE OF THE OPEN SERVICE POLICY**

12. In 2014 and 2015, the Department of Defense (“DOD”) began a review of whether transgender people should be permitted to serve openly in the Armed Forces. In July 2015, then-Secretary of Defense Ashton Carter issued an order establishing a Working Group to carry out the analysis of this issue. It is my understanding that the Working Group met to discuss issues relating to military service by transgender people over the course of about a year, consulting personnel, training, readiness, and medical specialists from across the Department of Defense. The Working Group also consulted civilian medical professionals of which I was one. To assist the Working Group, I went to the Pentagon to advise the Working Group, answered questions from military and civilian leadership, and provided advice on endocrinology and transgender health.

**CONSULTING FOR THE DEPARTMENT OF DEFENSE PANEL OF EXPERTS**

13. Following his July announcement to the public over Twitter, President Donald Trump released a memorandum (“August 25 Memorandum”) containing a formal directive to the current Secretary of Defense, Secretary James N. Mattis, and the Secretary of Homeland Security that, among other things, required the Secretary of Defense, in consultation with the Secretary of Homeland Security, to “submit to [the President] a plan for implementing” the ban on service by transgender people within six months.

14. Secretary Mattis, in turn, set up a process for “developing an Implementation Plan on military service by transgender individuals, in which the Deputy Secretary of Defense and the

Vice Chairman of the Joint Chiefs of Staff would be “supported by a panel of experts.” (“Review Panel”).

15. I reprised my earlier role as an advisor to the Working Group by serving as one of the outside expert consultants for the Review Panel. On November 9, 2017, Dr. Jillian Shipherd, a Clinical Psychologist and Director of the LGBT Health Program at the Veterans Health Administration; Dr. Loren Schechter, Visiting Clinical Professor of Surgery at the University of Illinois in Chicago and Director of the Center for Gender Confirmation Surgery at Weiss Memorial Hospital in Chicago; and I met with the Review Panel. About 15 to 20 people were present. Some of them were the same people who were on the Working Group conducted under Secretary of Defense Ashton Carter.

#### **A. COSTS**

16. After some preliminary discussion, costs of medical care for transgender service members did not appear to be a big concern for the Review Panel because the cost figures associated with transgender military health services were so low relative to the costs of other health conditions and to the overall military health budget.

#### **B. DEPLOYABILITY**

17. The Review Panel’s main focus was deployability, and in particular, the impact of hormone treatment on deployability. The Review Panel members also wanted information regarding how long an already-serving member of the Armed Forces would have to be on leave, nondeployable, or on limited duty as a result of initiating or being on hormone therapy as part of transgender medical treatment. In response to questions and in discussions, I stated that based on current research, I believe that the initiation of hormone therapy or being on hormone therapy would not prevent a servicemember from carrying out their military duties.

18. Secretary Mattis's February 22 Memorandum to the President cites the Endocrine Society Guidelines that I worked to develop to say that a person needs blood work to be done by a laboratory every 90 days for the first year of hormone therapy.<sup>2</sup> This is a misrepresentation of what my colleagues and I wrote in the Endocrine Society Guidelines. The Endocrine Society Guidelines suggest that clinicians measure hormone levels during treatment to ensure that "administered sex steroids are maintained in the normal physiologic range for the affirmed gender."<sup>3</sup> They also state, "We suggest regular clinical evaluation for physical changes and potential adverse changes in response to sex steroid hormones and laboratory monitoring of sex steroid hormone levels every 3 months during the first year of hormone therapy for transgender males and females and then once or twice yearly."<sup>4</sup>

19. The language we used made clear this was just a *suggestion*, not a requirement. The 3-month schedule is one that facilitates a relatively rapid dose advancement regimen within medically accepted standards. But that is not to say that a slower regimen would be less safe or not medically acceptable.

20. The Guidelines were written to aid endocrinologists in providing care for transgender patients. They do not state mandatory or essential treatment protocols.

21. When it is not practicable to perform quarterly blood work in the first year of hormone therapy, the patient's medication may simply be maintained at the prescribed level. The quarterly blood work is not necessary care. A doctor should check blood work after changing a

---

<sup>2</sup> Pages 22 and 33.

<sup>3</sup> Para. 3.3

<sup>4</sup> Para. 4.1.

patient's dose, but if a deployed service member cannot have a doctor check blood work, a patient can be maintained at the last known safe dose with no negative health consequences and no impact on readiness.

22. When I met with the Review Panel, I explained that while hormone therapy is necessary medical treatment for some transgender patients, temporarily (even for up to a 12 month deployment period where laboratory monitoring was not available) freezing the level of hormones a service member receives does not risk any provision of inadequate treatment; nor does it pose any medical or mental health risks *per se*.

23. The February 22 Memorandum is not consistent with the statements and recommendations I made when I met with the Review Panel.

24. There is no genuine issue regarding whether hormones can be taken into the field just as other medications are. Hormone therapies do not generally require special care or treatment such as refrigeration. There are versions that are stable and transportable.

25. A person receiving hormone therapy is in a steady state with hormones within weeks. There are no negative mental health consequences associated with not changing those levels for an extended period of time once a person's levels are in steady state.

26. The February 22 Memorandum states that "the available information indicates that there is inconclusive scientific evidence that the serious problems associated with gender dysphoria can be fully remedied through transition-related treatment and that, even if it could, most persons requiring transition-related treatment could be non-deployable for a potentially significant amount of time."<sup>5</sup> As an expert in the field of endocrinology and transgender health, I

---

<sup>5</sup> Page 35.

do not agree with this statement. My remarks to the Review Panel are not consistent with that conclusion.

### **C. LETHALITY**

27. The Review Panel was also interested in lethality. I believe, and so stated, that there is no known correlation between hormone levels and lethality.

### **CONCLUSION**

28. The February 22 Memorandum does not reflect the recommendations that I made to the Review Panel. As an expert qualified in the field of endocrinology and transgender health, it is my opinion that the February 22 Memorandum does not reflect the established scientific literature in this area. Based on my understanding of current data, statements that transgender people will be limited in their readiness to deploy based on hormone therapy needs are incorrect.

I declare under the penalty of perjury that the foregoing is true and correct.

DATED: May 14, 2018

  
\_\_\_\_\_  
Joshua D. Safer, M.D.

# EXHIBIT A

## CURRICULUM VITAE

**Joshua D. Safer, MD, FACP**

**March 1, 2018**

Office Address: 17 E. 102<sup>nd</sup> Street, Room D-240

New York, NY 10128

Tel: (212) 241-5484

E-mail: [jsafer0115@gmail.com](mailto:jsafer0115@gmail.com)

### Academic Training

1990 MD University of Wisconsin School of Medicine, Madison, WI  
1986 BS University of Wisconsin, Madison, WI, Economics

### Postdoctoral Training

1994-1996 Clinical and Research Fellow, Endocrinology, under Fredric Wondisford, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA  
1993-1994 Clinical Fellow, Endocrinology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA  
1990-1993 Intern and Resident, Department of Medicine, The Mount Sinai School of Medicine, Beth Israel Medical Center, New York City, NY

### Academic Appointments

2018-present Senior Faculty, Icahn School of Medicine at Mount Sinai, New York, NY  
2006-2018 Associate Professor of Medicine and Molecular Medicine, Boston University School of Medicine  
1999-2006 Assistant Professor of Medicine, Boston University School of Medicine  
1996-1999 Instructor in Medicine, Harvard Medical School  
1993-1996 Fellow in Medicine, Harvard Medical School

### Hospital Appointments

2018-present Staff Physician, Department of Medicine, The Mount Sinai Hospital, New York City, NY  
2018-present Staff Physician, Department of Medicine, Mount Sinai Beth Israel Medical Center, New York City, NY  
1999-2018 Staff Physician, Department of Medicine, Boston University Medical Center, Boston, MA  
2001-2006 Staff Physician, Veterans Administration Boston Health Care System, Boston, MA  
1996-1999 Staff Physician, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA  
1990-1993 House Staff, Department of Medicine, Beth Israel Medical Center, New York City, NY

### Other Medical Staff Appointments

2004-2013 Staff Physician, Massachusetts Institute of Technology Medical Center, Cambridge, MA  
1994-1999 Physician, Adult Urgent Care, Harvard Vanguard Medical Associates, Boston, MA  
1987-1996 Captain, United States Army Reserve, Medical Corps

**Joshua D. Safer, MD, FACP**

**Honors:**

2017	Lesbian, Gay, Bisexual and Transgender Health Award, Massachusetts Medical Society
2012	Outstanding Service Award, Association of Program Directors in Endocrinology and Metabolism
2007	Fellow, American College of Physicians
2004	Boston University School of Medicine Outstanding Student Mentor Award
2001	Abbott Thyroid Research Advisory Council Award
1996	Knoll Thyroid Research Clinical Fellowship Award, Endocrine Society
1995	Trainee Investigator Award for Excellence in Scientific Research, American Federation for Clinical Research (AFCR)
1994	Trainee Investigator Award for Excellence in Scientific Research, AFCR
1990	The University of Wisconsin Medical Alumni Association Award
1988-1990	Senior Class President, University of Wisconsin, School of Medicine

**Licensure and Certification**

1997	Board Certification in Endocrinology, Diabetes and Metabolism, American Board of Internal Medicine, recertified 2007, 2017
1994	Board Certification in Internal Medicine, American Board of Internal Medicine, recertified 2007
1993	MA License Registration #77459
1990	New York License Registration #187263-1

**Departmental and University Committees**

***Boston Medical Center***

2016-2018	Physician Satisfaction Task Force, Department of Medicine
2016-2018	Transgender Patient Task Force
2006-2017	Pharmacy and Therapeutics Committee, Health Net Plan

***Boston University School of Medicine***

2009-2018	Admissions Committee
2005	Review Committee, Department of Medicine Pilot Project Grants
2000	Residency and Fellowship Core Curriculum Committee,
2000-2018	Internship Selection Committee, Residency Program in Medicine

***Boston University Goldman School of Dental Medicine***

2003-2018	Course Directors Committee, Goldman School of Dental Medicine
-----------	---

**Teaching Experience and Responsibilities**

***Tufts University School of Medicine***

2016-2018	Lecturer in Endocrinology, Second-year Pathophysiology Course
-----------	---

***Boston University School of Medicine***

**Joshua D. Safer, MD, FACP**

2003-2018 Course Director, Disease and Therapy - Endocrinology Section  
1999-2018 Regular lectures to medical students, residents, and fellows on thyroid disease, diabetes insipidus, and transgender medicine

***Boston University Goldman School of Dental Medicine***

2002-2018 Course Director, General Medicine and Dental Correlations  
2002-2018 Course Director, Medical Concerns in the Dental Patient

**Joshua D. Safer, MD, FACP****Major Mentoring Activities****Physician Career/Peer Advising**

<b>Year</b>	<b>Mentee</b>	<b>Most Recent Title</b>
1995-present	<b>Cohen, Ron, MD</b> Ongoing career guidance	<ul style="list-style-type: none"> <li>▪ Associate Professor of Medicine and Interim Chief, Division of Endocrinology, University of Chicago School of Medicine</li> </ul>
1999-present	<b>Tangpricha, Vin, MD, PhD</b> Ongoing career guidance	<ul style="list-style-type: none"> <li>▪ Associate Professor of Medicine and Program Director, Endocrinology Fellowship, Emory University School of Medicine</li> </ul>
2003-present	<b>McDonnell, Marie, MD</b> Ongoing career guidance	<ul style="list-style-type: none"> <li>▪ Director, Inpatient Diabetes Service, Brigham and Women's Hospital</li> </ul>
2003-present	<b>Arum, Seth, MD</b> Ongoing career guidance.	<ul style="list-style-type: none"> <li>▪ Faculty, Endocrinology Section, University of Massachusetts Medical Center</li> </ul>
2004-present	<b>Ananthakrishnan, Sonia, MD</b> Ongoing career guidance	<ul style="list-style-type: none"> <li>▪ Evans Educator, Endocrinology Section, Boston University Medical Center</li> </ul>
2007-present	<b>Vimalananda, Varsha, MD</b> Ongoing career guidance	<ul style="list-style-type: none"> <li>▪ Faculty, Endocrinology Section, Boston University Medical Center and Boston VA Hospital</li> </ul>
2008-present	<b>Port, Ava, MD</b> Ongoing career guidance	<ul style="list-style-type: none"> <li>▪ Faculty, Endocrinology Section, University of Maryland Medical Center</li> </ul>
2009-2013	<b>Choong, Karen, MD</b> Ongoing career guidance	<ul style="list-style-type: none"> <li>▪ Private Practice, MA</li> </ul>
2009-2010	<b>Kannan, Subramanian, MD</b> Ongoing career guidance	<ul style="list-style-type: none"> <li>▪ Completed Endocrinology Fellowship Cleveland Clinic</li> </ul>
2010-present	<b>Spitzer, Matthew, MD</b> Ongoing career guidance	<ul style="list-style-type: none"> <li>▪ Private Practice, Amherst, MA</li> </ul>
2011-present	<b>Steenkamp, Devin, MD</b> Ongoing career guidance	<ul style="list-style-type: none"> <li>▪ Faculty, Endocrinology Section, Boston University Medical Center</li> </ul>
2014-present	<b>Thomas, Dylan, MD</b> Ongoing career guidance	<ul style="list-style-type: none"> <li>▪ Endocrinology Fellow, Department of Medicine, Boston University Medical Center</li> </ul>
2017-present	<b>Korpaisarn, Sira, MD</b> Ongoing career guidance	<ul style="list-style-type: none"> <li>▪ Endocrinology Fellow, Department of Medicine, Boston University Medical Center</li> </ul>

**Joshua D. Safer, MD, FACP****Student Research Mentor and/or Thesis Advisor**

<b>Year</b>	<b>Mentee</b>	<b>Most Recent Title</b>
1996-1997	<b>Martin, Andrew</b> Used DNA manipulation and tissue culture techniques to analyze <i>in vitro</i> functional impact of thyroid hormone resistance mutations.	▪ Matriculated University of Virginia September, 1997
1998	<b>Wong, Jenny</b> Used DNA manipulation and tissue culture techniques to analyze <i>in vitro</i> functional impact of thyroid hormone resistance mutations.	▪ Matriculated Harvard College September, 1998
1998	<b>Song, Hyang Yeon</b> Used DNA manipulation and tissue culture techniques to analyze <i>in vitro</i> functional impact of thyroid hormone resistance mutations.	▪ Graduated Mount Holyoke College
1999-2001	<b>Fraser, Lisa</b> Used DNA manipulation and tissue culture techniques to analyze <i>in vitro</i> functional impact of thyroid hormone resistance mutations. Learned and performed tissue culture assays in order to assess thyroid hormone action on skin cell lines. Assisted in design and implementation of experiments to assess thyroid hormone action on the skin of animals.	▪ Working in biotechnology
2000	<b>Hoa, Michael</b> Learned and performed tissue culture assays in order to assess thyroid hormone action on skin cell lines. Assisted in design and implementation of experiments to assess thyroid hormone action on the skin of animals.	▪ Matriculated Boston University School of Medicine September, 2000
2001-2004	<b>Crawford, Tara</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines. Assisted in design and implementation of experiments to assess thyroid hormone action on the skin of animals.	▪ Works in recruitment for Ross Medical School
2003-2004	<b>Vaghasia, Pramil</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines	▪ Graduated Boston University, 2004
2003	<b>Ladhani, Anil</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ Graduated Boston University, 2004
2003	<b>Belardo, Sheila</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ Graduated Boston University, 2005

**Joshua D. Safer, MD, FACP**

<b>Year</b>	<b>Mentee</b>	<b>Most Recent Title</b>
2004	<b>Mohan, Shaulnie</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ Graduated Boston University, 2005; matriculated Boston University School of Medicine
2004	<b>Patel, Nathan</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ Graduated Boston University, 2005
2004	<b>Sharma, Aman</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ Graduated Boston University, 2005; matriculated SUNY-Downstate School of Medicine
2006-2007	<b>Holland (now Rogers), Kathryn</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines. Assisted in design and implementation of experiments to assess thyroid hormone action on the skin of animals. Learned and performed in vivo methodologies with mice. Coauthored a publication from the data.	▪ Graduated Boston University, 2005; working as a school teacher
2006-2008	<b>Huang, Max</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines. Assisted in design and implementation of experiments to assess thyroid hormone action on the skin of animals. Learned and performed in vivo methodologies with mice. First authored a poster presented at a national meeting. First authored a publication from the data.	▪ MS from Boston University; matriculated medical school
2006-2008	<b>Mehta, Meetal</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines. Coauthored a publication from the data.	▪ MS from Boston University; matriculated medical school
2006-2007	<b>O'Mara, Rosemary</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines. Assisted in design and implementation of experiments to assess thyroid hormone action on the skin of animals. Learned and performed in vivo methodologies with mice. Coauthored a publication from the data.	▪ BA from Boston University

**Joshua D. Safer, MD, FACP**

<b>Year</b>	<b>Mentee</b>	<b>Most Recent Title</b>
2007	<b>Abuzahra, Hilal</b> Assisted in design and implementation of experiments to assess thyroid hormone action on the skin of animals. Learned and performed in vivo methodologies with mice. Coauthored a publication from the data.	▪ MS from Boston University; matriculated Boston University School of Medicine
2007	<b>Tannenbaum, Andrew</b> Assisted in design and implementation of experiments to assess thyroid hormone action on the skin of animals. Learned and performed in vivo methodologies with mice. Coauthored a publication from the data.	▪ MS from Boston University; matriculated Boston University School of Medicine
2007-2008	<b>Yoo, David</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ MS from Boston University
2007-2008	<b>Pagano, Joe</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ MS from Boston University
2007-2009	<b>Bhakit, Mena</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines. Assisted in design and implementation of experiments to assess thyroid hormone action on the skin of animals. Learned and performed in vivo methodologies with mice. Coauthored a publication from the data.	▪ MS from Boston University; matriculated medical school
2007-2008	<b>Chan, Yvonne</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ MS from Boston University; matriculated graduate school
2007-2008	<b>Lee, Monica</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ MS from Boston University
2007-2008	<b>Grasso, Victoria</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ MS from Boston University
2007-2008	<b>Bokhari, Matthew</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ BA from Boston University

**Joshua D. Safer, MD, FACP**

<b>Year</b>	<b>Mentee</b>	<b>Most Recent Title</b>
2008-2010	<b>Watto, Matthew</b> Career guidance.	▪ Matriculated Temple University Internal Medicine Residency Program
2008-2011	<b>Agee, Erin</b> Master's Thesis Advisor. Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ MS from Boston University
2009-2010	<b>Wang, Yun</b> Master's Research and Thesis Advisor. Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ MS from Boston University
2009-2011	<b>Nishtala, Arvind</b> Research Advisor. Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ Matriculated Medical School, Boston University
2009-2010	<b>Chen, Bridgett</b> Master's Research Project and Thesis Advisor. Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ Matriculated Medical School, Albany Medical College
2009	<b>Esochaghi, Sorochi</b> Master's Research Project and Thesis Advisor. Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ MS from Boston University
2009-2011	<b>Kim, Kyeonghee</b> Master's Research and Thesis Advisor. Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ MS from Boston University
2010-2011	<b>Faruqi, Adnan</b> Master's Research Project and Thesis Advisor. Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ MS from Boston University
2010-2011	<b>Fink, Kyle</b> Master's Research Project and Thesis Advisor. Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ Matriculated Medical School at New York Medical College

**Joshua D. Safer, MD, FACP**

<b>Year</b>	<b>Mentee</b>	<b>Most Recent Title</b>
2010-2011	<b>Heath, Alyson</b> Master's Thesis Advisor. Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ MS from Boston University
2010-2011	<b>Mouchati, Alex</b> Master's Research and Thesis Advisor. Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines. First authored an abstract at a local meeting.	▪ MS from Boston University
2010-2011	<b>Porter, Drew</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ BS from Boston University
2010	<b>Rosenbaum, Lucy</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ Matriculated Boston University School of Medicine
2011-2012	<b>Stratton, Michael</b> Master's Research and Thesis Advisor. Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ Matriculated Boston University School of Medicine
2011-2012	<b>Feeley, Brigid</b> Master's Research and Thesis Advisor. Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ MS from Boston University
2011-2012	<b>Gonzales, Christopher</b> Master's Research and Thesis Advisor. Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ MS from Boston University
2011-2012	<b>Mahmood, Sundis</b> Master's Research and Thesis Advisor. Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ MS from Boston University

**Joshua D. Safer, MD, FACP**

<b>Year</b>	<b>Mentee</b>	<b>Most Recent Title</b>
2011-2012	<b>Berman, Reena</b> Research and undergraduate thesis advisor. Assisted in design and implementation of experiments to assess thyroid hormone action on the skin of animals. Learned and performed in vivo methodologies with mice. First authored a poster presentation at a local meeting from the data.	▪ BA from Boston University
2011-2012	<b>Dwivedi, Sashank</b> Research advisor. Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ BA from Boston University
2012-2013	<b>Carey, Katelyn</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ MS from Boston University
2012-2013	<b>Moroney, James</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ MS from Boston University
2012-2013	<b>Sayed, Sabina</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess thyroid hormone action on skin cell lines.	▪ MS from Boston University
2012-present	<b>Meyers, Steven</b> Developed and analyzed clinical data sets for quality projects and research projects in Transgender Medicine. First author of two publications.	▪ BS from Hampshire College
2012-present	<b>Gardner, Ivy</b> Learned and performed tissue culture/gene expression/protein expression assays in order to assess androgen action on endometrial cell lines. First author of data presented at two meetings. First author of publication.	▪ MD from Boston University; matriculated general surgery residency
2012-2013	<b>Bonzagni, Anthony</b> Developed and analyzed data for research projects in Transgender Medicine.	▪ MS from Boston University
2012-2014	<b>Ma, Peter</b> Developed and analyzed data for research projects in Transgender Medicine.	▪ BS from Boston University
2013-present	<b>Fong, Elias</b> Developed and analyzed data for research projects in Transgender Medicine.	▪ BS from Boston University

**Joshua D. Safer, MD, FACP**

<b>Year</b>	<b>Mentee</b>	<b>Most Recent Title</b>
2013-present	<b>Weinand, Jamie</b> Developed and analyzed data for research projects in Transgender Medicine. First author of data presented at two meetings. First author of publication.	▪ MD from Boston University; matriculated family medicine residency
2014-present	<b>Eriksson, Sven</b> Developed and analyzed data for research projects in Transgender Medicine. First author of publication.	▪ MS from Boston University; matriculated medical school
2015-present	<b>Liang, Jennifer</b> Developed and analyzed data for research projects in Transgender Medicine. First author of two publications	▪ Medical Student at Boston University
2015-present	<b>Lu, Simon</b> Developed and analyzed data for research projects in Transgender Medicine. Publication co-author	▪ MD from Boston University; matriculated obstetrics-gynecology residency
2015-present	<b>Qian, Ray</b> Developed and analyzed data for research projects in Transgender Medicine. First author of publication.	▪ Medical Resident at Boston University Medical Center
2016-present	<b>Kailas, Maya</b> Developed and analyzed data for research projects in Transgender Medicine. First author of publication.	▪ Medical Student at Boston University
2016-present	<b>Jolly, Divya</b> Developed and analyzed data for research projects in Transgender Medicine. Manuscript in progress	▪ Medical Anthropology Graduate Student at Boston University
2016-present	<b>Chan, Kelly</b> Developed and analyzed data for research projects in Transgender Medicine. Manuscript in progress	▪ Masters Student at Harvard University
2017-present	<b>Park, Jason</b> Developed and analyzed data for research projects in Transgender Medicine. Manuscript in progress	▪ Medical Student at Boston University
2017-present	<b>Bisson, Jason</b> Developed and analyzed data for research projects in Transgender Medicine. Manuscript in progress	▪ College Student at Northeastern University

**Joshua D. Safer, MD, FACP**

**Major Administrative Responsibilities**

- 2018-present Executive Director, Center for Transgender Medicine and Surgery, Mount Sinai Health System, New York City, NY
- 2016-2018 Medical Director, Center for Transgender Medicine and Surgery, Boston Medical Center, Boston, MA
- 2007-2018 Director, Medical Education, Endocrinology Section, Boston University School of Medicine, Boston, MA
- 2007-2018 Program Director, Endocrinology Fellowship Training, Boston University Medical Center, Boston, MA
- 1999-2003 Director, Thyroid Clinic, Boston Medical Center, Boston, MA

**Other Professional Activities**

**Professional Societies: Memberships**

- 2016-present United States Professional Association for Transgender Health (USPATH)
- 2014-present World Professional Association for Transgender Health (WPATH)
- 2007-present Association of Program Directors in Endocrinology and Metabolism (APDEM)
- 2007-present Association of Specialty Professors (ASP), Alliance of Academic Internal Medicine (AAIM)
- 1999-present American Association of Clinical Endocrinologists
- 1998-present American Thyroid Association
- 1995-present Endocrine Society
- 1994-present American College of Physicians
- 1994-1996 American Federation for Medical Research
- 1993-present MA Medical Society

**Professional Societies: Offices Held and Committee Assignments**

**International**

***International Olympic Committee (IOC)***

- 2017-present Drafting Group Member, Medical Guidelines, International Olympic Committee

***World Professional Association for Transgender Health (WPATH)***

- 2016-present Writing Committee Member, Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People
- 2016-present Co-Chair, Scientific Committee, International Meeting, Buenos Aires - 2018
- 2015-2016 Chair, Scientific Committee, International Meeting, Amsterdam - 2016
- 2015-present Task Force Member, Global Education Initiative
- 2015-present Media Liaison

***TransNet – International Consortium for Transgender Medicine and Health Research***

- 2014-present Secretary and Co-Chair, Steering Committee

**Joshua D. Safer, MD, FACP**

**National**

***United States Professional Association for Transgender Health (USPATH)***

2018-present President

***Alliance of Academic Internal Medicine***

2016-present Chair, Compliance Committee

2016-2017 Committee member, Compensation

2015-2016 President, Association of Specialty Professors (ASP)

2014-2017 Council member

2014-present Task Force member, Program Planning

2014-present Work Group member, Survey Center

2013-2015 Chair, Program Planning Committee, ASP

2012-2017 Council member, ASP

2012-2013 Chair, Membership Services Committee, ASP

2010-2015 Chair, Program Directors Site Visit Training Seminar, ASP

2007-2013 Committee member, Membership Services, ASP

***American College of Physicians***

2016-present Council of Subspecialty Societies member

***Endocrine Society***

2017-present Advisory Board member, Transgender/Disorders of Sex Development

2017-present Committee member, Clinical Endocrine Education

2014-present Media Liaison for Transgender Medicine

2014-2017 Task Force member, Endocrine Treatment of Transgender Persons Clinical Practice Guideline

***American Board of Internal Medicine***

2013-present Task Force member, Endocrinology Procedures

2013 Task Force member, ASP/AAIM/ACGME/ABIM Joint Next Accreditation System Internal Medicine Subspecialty Milestones

***Association of Program Directors in Endocrinology and Metabolism***

2017-present Secretary-Treasurer

2012-present Task Force member, Next Accreditation System Endocrinology Milestones

2011-2012 Task Force member, Procedures Accreditation

2010-2012 Council member

2009-2016 Chair, Site Visit/Curriculum Web-Toolbox Committee

***American Thyroid Association***

2006-2009 Publications Committee member

2004 Program Committee member

**Editorships and Editorial Boards**

2018-present Associate Editor, *Transgender Health*

2017-present Editorial Advisory Board, *Endocrine News*

**Joshua D. Safer, MD, FACP**

2016-present Transgender Section Co-Editor, *UpToDate*  
 2015-present Editorial Board, *Transgender Health*  
 2015-present Editorial Board, *International Journal of Transgenderism*  
 2013-present Associate Editor, *Journal of Clinical & Translational Endocrinology*  
 2007-present Editorial Board, *Endocrine Practice*

**External Medical Advising and Consulting****International**

2016-present International transgender athlete guidelines, Medical and Scientific Commission, International Olympic Committee

**National**

2017-present Transgender medical and surgical treatment, National Collegiate Athletic Association,  
 2017-present Safety for transgender medical treatment, Food and Drug Administration, United States  
 2015-present Transgender workforce and military readiness, Department of Defense, United States  
 2014 Transgender prison population health, Federal Bureau of Prisons, United States

**Regional**

2011-present Transgender prison population health, Massachusetts Department of Correction

**Past Other Support**

2015-2016 R13 HD084267, **Multi-PI: Joshua D. Safer**, TransNet: Developing a Research Agenda in Transgender Health and Medicine

2014-2015 Boston Foundation, Equality Fund, **PI: Joshua D. Safer**, Pilot Program to Educate Physicians in Transgender Medicine

2013-2014 Evans Foundation, **PI: Joshua D. Safer**, A Pilot Curriculum in Transgender Medicine

2001-2003 Thyroid Research Advisory Council, **PI: Joshua D. Safer**, Thyroid Hormone Action on Skin

2001-2002 Evans Foundation, **PI: Joshua D. Safer**, Thyroid Hormone Action on Skin

1996-2001 K08 DK02423, **PI: Joshua D. Safer**, Characterization of Central Resistance to Thyroid Hormone

**Joshua D. Safer, MD, FACP**

**Conferences Organized**

**International Conferences**

***World Professional Association for Transgender Health (WPATH)***

June, 2018 Bi-annual meeting, Scientific Co-Chair, Buenos Aires, Argentina (scheduled)

June, 2016 Bi-annual meeting, Scientific Co-Chair, Amsterdam, Netherlands

November, 2015 Global Education Initiative, inaugural conference, Chicago, IL

***TransNet – International Consortium for Transgender Health and Medicine Research***

May, 2016 International meeting to set transgender medicine research priorities, Amsterdam, Netherlands

May, 2015 NIH conference to set transgender medicine research priorities, Bethesda, MD

June, 2014 Inaugural meeting, Chicago, IL

**National Conferences**

April, 2018 Live Surgery Course for Gender Affirmation Procedures, Mount Sinai Hospital and WPATH, New York City, NY (scheduled)

January, 2017 United States Professional Association for Transgender Health (USPATH) bi-annual meeting, Los Angeles, CA

November, 2015 NIH/Alliance for Academic Internal Medicine - Physician Researcher Workforce Taskforce Meeting, Washington, DC

October, 2015 National Internal Medicine Subspecialty Summit, Atlanta, GA

June, 2013 Special Symposium: “Transgender Medicine – What Every Physician Should Know” Annual Meeting of the Endocrine Society, San Francisco, CA

April, 2011 2011 ASP Accreditation Seminar "Meeting the ACGME and RRC-IM Standards for Successful Fellowship Programs" Arlington, VA

***Alliance for Academic Internal Medicine***

April, 2015 2015 ASP Accreditation Seminar “Moving Your Fellowship Program Forward” Spring Meeting, Houston, TX

April, 2014 2014 ASP Accreditation Seminar “NAS for Medical Subspecialties Is Almost Here” Spring Meeting, Nashville, TN

May, 2013 2013 ASP Accreditation Seminar “A Changing Landscape in Subspecialty Fellowship Education” Spring Meeting, Lake Buena Vista, FL

**Joshua D. Safer, MD, FACP**

April, 2012 2012 ASP Accreditation Seminar “Meeting ACGME and RRC-IM Standards for Successful Fellowship Programs” Spring Meeting, Atlanta, GA

**Invited Lectures and Presentations**

**International**

February, 2017 “A 21<sup>st</sup>-Century Framework to for Transgender Medical Care” Sheba Hospital, Tel Aviv, Israel

October, 2016 “A 21<sup>st</sup>-Century Approach to Hormone Treatment of Transgender Individuals” EndoBridge, Antalya, Turkey

May, 2016 “Transgender Women” International Olympic Committee Headquarters, Lausanne, Switzerland

October, 2015 “Workshop on Guidelines for Transgender Health Care” Canadian Professional Association for Transgender Health, Halifax, NS

March, 2015 “Endocrinology - Hormone Induced Changes” Transgender Health Care in Europe, European Professional Association for Transgender Health, Ghent, Belgium

June, 2014 “What to Know to Feel Safe Providing Hormone Therapy for Transgender Patients” International Congress of Endocrinology, Chicago, IL

September, 2011 “Transgender Therapy – The Endocrine Society Guidelines” World Professional Association for Transgender Health, Atlanta, GA

February, 2007 “Treating skin disease by manipulating thyroid hormone action” Grand Rounds, Meier Hospital, Kfar Saba, Israel

March, 2004 “New Directions in Thyroid Hormone Action: Skin and Hair” Grand Rounds, Meier Hospital, Kfar Saba, Israel

**National**

October, 2018 “Transgender Therapy – The Endocrine Society Guidelines” Endocrine Society: Clinical Endocrinology Update, Anaheim, CA

September, 2018 “Transgender Therapy – The Endocrine Society Guidelines” Endocrine Society: Clinical Endocrinology Update, Miami, FL

September, 2018 “Current Guidelines and Strategy for Hormone Treatment of Transgender Individuals” Minnesota-Midwest Chapter - American Association of Clinical Endocrinologists Annual Meeting, Minneapolis, MN (scheduled)

July, 2018 “Current Guidelines and Strategy for Hormone Treatment of Transgender Individuals” Upper Ohio Valley Chapter - American Association of Clinical Endocrinologists Annual Meeting, Indianapolis, IN (scheduled)

**Joshua D. Safer, MD, FACP**

- May, 2018 “A 21<sup>st</sup>-Century Strategy for Hormone Treatment of Transgender Individuals” American Association of Clinical Endocrinologists Annual Meeting, Boston, MA (scheduled)
- March, 2018 “21<sup>st</sup>-Century Strategies for Transgender Hormone Care” New Jersey Chapter - American Association of Clinical Endocrinologists Meeting, Morristown, NJ
- February, 2018 “A Strategy for the Medical Care of Transgender Individuals” Keynote Address for the International Society for Clinical Densitometry Annual Meeting, Boston, MA
- November, 2017 “A 21<sup>st</sup>-Century Strategy for Hormone Treatment of Transgender Individuals” National Transgender Health Summit, Oakland, CA
- September, 2017 “Transgender Therapy – The Endocrine Society Guidelines” Endocrine Society: Clinical Endocrinology Update, Chicago, IL
- May, 2017 “Transgender Medicine – a 21st Century Strategy for Patient Care” University of Arizona College of Medicine, Tucson, AR
- April, 2017 “Transgender Care Across the Age Continuum” Annual Meeting of the Endocrine Society, Orlando, FL
- March, 2017 “A 21<sup>st</sup>-Century Approach to Hormone Treatment of Transgender Individuals” Brown University School of Medicine, Providence, RI
- March, 2017 “What to Know: A 21<sup>st</sup>-Century Approach to Transgender Medical Care” United States Food and Drug Administration (FDA), Washington, DC
- February, 2017 “A 21<sup>st</sup>-Century Approach to Transgender Medical Care” United States Professional Association for Transgender Health, Los Angeles, CA
- February, 2017 “A 21<sup>st</sup>-Century Approach to Hormone Treatment of Transgender Individuals” Southern States American Association of Clinical Endocrinologists Annual Meeting, Memphis, TN
- December, 2016 “Transgender Medical Care in the United States Armed Forces” Global Education Initiative, World Professional Association for Transgender Health, Arlington, VA
- December, 2016 “Foundations in Hormone Treatment” Global Education Initiative, World Professional Association for Transgender Health, Arlington, VA
- November, 2016 “Developing a Transgender/Gender-Identity Curriculum for Medical Students” Association of American Medical Colleges National Meeting, Seattle, WA
- September, 2016 “A 21<sup>st</sup>-Century Approach to Hormone Treatment of Transgender Individuals” Endocrine Society: Clinical Endocrinology Update, Seattle, WA
- August, 2016 “A 21<sup>st</sup>-Century Approach to Hormone Treatment of Transgender Individuals” Oregon Health and Science University Ashland Endocrine Conference, Ashland, OR

**Joshua D. Safer, MD, FACP**

- March, 2016 “State-of-the-Art: Use of Hormones in Transgender Individuals” Annual Meeting of the Endocrine Society, Boston, MA
- October, 2015 “What Every Endocrinologist Should Know to Feel Safe Providing Hormone Therapy for Transgender Patients” University of Utah School of Medicine, Salt Lake City, UT
- April, 2015 “What to Know –to Feel Safe Providing Hormone Therapy for Transgender Patients” Pritzker School of Medicine, University of Chicago, Chicago, IL
- March, 2015 “What to Know –to Feel Safe with Hormone Therapy for Transgender Patients” Annual Transgender Health Symposium, Medical College of Wisconsin, Milwaukee, WI
- May, 2014 “Transgendorocrinology” Annual Meeting of the American Association of Clinical Endocrinologists, Las Vegas, NV
- May, 2013 “Transgender Therapy – Hormone Action and Nuance” National Transgender Health Summit, Oakland, CA
- April, 2013 “Transgender Therapy – What Every Provider Needs to Know” Empire Conference: Transgender Health and Wellness, Albany, NY
- April, 2013 “Transgender Therapy – What Every Endocrinologist Needs to Know” University of Maryland School of Medicine, Baltimore, MD
- November, 2012 “Transgender Therapy – What Every Endocrinologist Should Know” New York University School of Medicine, New York, NY
- May, 2010 “Transgender Treatment: What Every Endocrinologist Needs to Know” Brown University School of Medicine, Providence, RI
- November, 2009 “New Directions in Thyroid Hormone Action: Skin and Hair” Emory University School of Medicine, Atlanta, GA
- November, 2009 “Primary Care Update in the Treatment of Thyroid Disorders” Emory University School of Medicine, Atlanta, GA
- October, 2008 “Topical Iopanoic Acid Stimulates Epidermal Proliferation through Inhibition of the Type 3 Thyroid Hormone Deiodinase” Annual Meeting of the American Thyroid Association, Chicago, IL
- February, 2005 “New Directions in Thyroid Hormone Action: Skin and Hair” Endocrinology Grand Rounds, University of Minnesota, Minneapolis, MN
- February, 2005 “Thyroid Hormone Action on Skin and Hair: What We Thought We Knew” Dermatology Grand Rounds, University of Minnesota, Minneapolis, MN
- December, 2004 “Transgender Therapy: The Role of the Endocrinologist” Endocrinology Grand Rounds, Brown Medical Center, Providence, RI

**Joshua D. Safer, MD, FACP**

November, 2003 “New Directions in Thyroid Hormone Action: Skin and Hair” Endocrinology Grand Rounds, Dartmouth Medical Center, Hanover, NH

**Regional**

February, 2018 “Transgender Medicine – 21<sup>st</sup> Century Strategies for Patient Care” Medicine Rounds, Newton-Wellesley Hospital, Newton, MA (scheduled)

October, 2017 “Transgender Medicine – 21<sup>st</sup> Century Strategies for Patient Care” Medicine Rounds, Beth Israel-Milton Hospital, Milton, MA

September, 2017 “Transgender Medicine – 21<sup>st</sup> Century Strategies for Patient Care” Obstetrics-Gynecology Grand Rounds, Brigham and Women’s Hospital, Boston, MA

June, 2017 “State-of-the-Art: Hormone Therapy for Transgender Patients” Reproductive Endocrinology Rounds, Massachusetts General Hospital, Boston, MA

May, 2017 “A 21<sup>st</sup>-Century Strategy for Medical Treatment of Transgender Individuals” Boston Medical Center and Boston University School of Medicine, Boston, MA

March, 2017 “A 21<sup>st</sup>-Century Strategy for Medical Treatment of Transgender Individuals” Tufts Medicine Grand Rounds, Boston, MA

January, 2017 “What to Know: A 21<sup>st</sup>-Century Approach to Transgender Medical Care” Internal Medicine Rounds, Brigham and Women’s Hospital, Boston, MA

March, 2016 “State-of-the-Art: Hormone Therapy for Transgender Patients” Obstetrics-Gynecology Rounds, Brigham and Women’s Hospital, Boston, MA

November, 2015 “What Every Endocrinologist Should Know to Feel Safe Providing Hormone Therapy for Transgender Patients” Endocrinology Rounds, Tufts Medical Center, Boston, MA

May, 2015 “What Every Endocrinologist Should Know to Feel Safe Providing Hormone Therapy for Transgender Patients” Endocrinology Rounds, Massachusetts General Hospital, Boston, MA

December, 2014 “What to Know to Feel Safe Providing Hormone Therapy for Transgender Patients” Endocrinology Rounds, Beth Israel Deaconess Medical Center, Boston, MA

November, 2013 “Transgender Therapy – What Every Physician Should Know” Medicine Grand Rounds, Boston Veterans Administration Hospital, Boston, MA

May, 2005 “Transgender Therapy: The Role of the Endocrinologist”, Endocrinology Rounds, Tufts-New England Medical Center, Boston, MA

January, 2004 “New Directions in Thyroid Hormone Action: Skin and Hair”, Endocrinology Rounds, Brigham and Women’s Hospital, Boston, MA

October, 1999 “The Many Faces of Hypothyroidism”, Medicine Grand Rounds, Bedford Veterans Administration Hospital, Bedford, MA

March 1, 2018

**Joshua D. Safer, MD, FACP**

**Institutional, Icahn School of Medicine at Mount Sinai, New York, NY**

April, 2018 “State of the Art Hormone Therapy for Transgender Patients”, Section of Infectious Disease

**Institutional, Boston University School of Medicine, Boston, MA**

March, 2017 “State of the Art Hormone Therapy for Transgender Patients”, Section of Infectious Disease

January, 2017 “What you need to know – to supervise care for our transgender patients at BMC”,  
Section of Endocrinology

February, 2016 “State of the Art Hormone Therapy for Transgender Patients”, Department of Medicine

November, 2015 “What the Family Medicine Physician Should Know to Feel Safe Providing Hormone Therapy  
for Transgender Patients”, Department of Family Medicine

November, 2014 “What the Anesthesiologist Should Know to Feel Safe Providing Hormone Therapy for  
Transgender Patients”, Department of Anesthesia

January, 2014 “Update on the Current Guidelines for Transgender Hormone Therapy”, Section of  
Endocrinology

October, 2011 “Transgender Therapy – What Every Physician Should Know”, Department of Medicine

February, 2011 “Current Guidelines for Transgender Hormone Therapy: What Every Endocrinologist Should  
Know”, Section of Endocrinology

November, 2005 “Thyroiditis and Other Insults to Thyroid Function” Core Curriculum in Adult Primary Care  
Medicine

November, 2005 “Interpretation of Thyroid Function Tests Made Easy” Core Curriculum in Adult Primary Care  
Medicine

January, 2005 “Transgender Therapy: The Role of the Endocrinologist” Endocrinology Grand Rounds

December, 2004 "Update in Endocrinology: Thyroid" Medicine Grand Rounds

January, 2004 “New Directions in Thyroid Hormone Action: Skin and Hair” Medicine Grand Rounds

March, 2003 “Thyroid Hormone Action on Hair and Skin” Endocrinology Grand Rounds

November, 1999 “Central Resistance to Thyroid Hormone – From Bedside to Bench” Endocrinology Grand  
Rounds

**Joshua D. Safer, MD, FACP**

**Curriculum development with external dissemination**

2014-present Web site for Association of Program Directors of Endocrinology and Metabolism (APDEM), which serves as *the primary resource for endocrinology fellowship program directors throughout the United States and Canada.*

- Sample curricula
- Streaming lectures to support specific curricular needs to fill programmatic gaps at certain programs
- New assessment forms that map skills to milestones that conform to Next Accreditation System (NAS) standards of the Accreditation Council for Graduate Medical Education (ACGME)

2013-present Dissemination of Transgender Medicine Curriculum with local modification to institutions in the United States and Canada

Curriculum adopted

**Johns Hopkins School of Nursing** (sample video:  
<http://vimeo.com/jhunursing/review/97477269/abbcf6d33a>)

**Ohio State University College of Medicine**

**University of British Columbia, Faculty of Medicine**

**University of Central Florida College of Medicine**

**Tufts University School of Medicine**

Curriculum in development

**Dartmouth School of Medicine**

**University of Vermont College of Medicine**

Work in progress in preparation for sharing transgender curriculum

Albany Medical College

Emory School of Medicine

George Washington University Medical School

Hofstra School of Medicine

University of California – San Diego School of Medicine

University of Kentucky College of Medicine

University of Louisville School of Medicine

University of Michigan Medical School

University of Minnesota Medical School

University of Nebraska School of Medicine

University of Pennsylvania School of Medicine

Washington University School of Medicine

**Joshua D. Safer, MD, FACP**

2013-2015 Co-author of the *Medical Subspecialty Reporting Milestones used for evaluation of Internal Medicine subspecialty medicine fellowship programs throughout the Unites States* by the Accreditation Council for Graduate Medical Education (ACGME).

<https://www.acgme.org/acgmeweb/Portals/0/PDFs/Milestones/InternalMedicineSubspecialtyMilestones.pdf>

2011-2014 Web site content expert for APDEM, which served as *the primary resource for endocrinology fellowship Program directors throughout the United States and Canada*. Materials included sample curricula, streaming lectures to support specific curricular needs to feel programmatic gaps at certain programs, and guidance dealing with ACGME site-visits

**Other curriculum development**

2016-present Curricular Content to teach transgender hormone therapy in the LGBT elective at Harvard Medical School

2016-present Curricular Content to teach transgender hormone therapy at Tufts University School of Medicine.

2011-present Fully revised curriculum for the Boston University Medical Center Fellowship Training Program in Endocrinology, Diabetes and Nutrition.

2010-present Curricula to teach transgender hormone therapy at Boston University School of Medicine.

2006-2014 Written examination in endocrinology to complement the multiple choice examination for medical students — validation relative to success later in medical school is in progress.

**Joshua D. Safer, MD, FACP****Bibliography: (ORCID  # 0000 0003 2497 8401)**Names of mentees are underlined throughout the bibliography section

\*\*5 currently most influential papers are noted with double asterisks

**Original, Peer-Reviewed Articles**

1. **Safer JD**, Langlois MF, Cohen R, Monden T, John-Hope D, Madura J, Hollenberg AN, Wondisford FE. Isoform variable action among thyroid hormone receptor mutants provides insight into pituitary resistance to thyroid hormone. *Mol Endocrinol* 1997;11(1):16-26. PMID 8994184
2. Langlois MF, Zanger K, Monden T, **Safer JD**, Hollenberg AN, Wondisford FE. A unique role of the beta-2 thyroid hormone receptor isoform in negative regulation by thyroid hormone - mapping of a novel amino-terminal domain important for ligand-independent activation. *J Biol Chem* 1997;272(40):24927-24933. PMID 9312095
3. **Safer JD**, Cohen RN, Hollenberg AN, Wondisford, FE. Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone. *J Biol Chem* 1998;273(46):30175-30182. PMID 9804773
4. **Safer JD**, O'Connor MG, Colan SD, Srinivasan S, Tollin SR, Wondisford FE. The TR-beta gene mutation R383H is associated with isolated central resistance to thyroid hormone. *J Clin Endocrinol Metab* 1999;84(9):3099-3109. PMID 10487671
5. **Safer JD**, Fraser LM, Ray S, Holick MF. Topically applied triiodothyronine stimulates epidermal proliferation, dermal thickening, and hair growth in mice and rats. *Thyroid* 2001;1(8):717-724. PMID 11525263
6. Tangpricha V, Chen BJ, Swan NC, Sweeney AT, de las Morenas A, **Safer JD**. Twenty-one gauge needles provide more cellular samples than twenty-five gauge needles in fine needle aspiration biopsy of the thyroid. *Thyroid* 2001;11(10):973-976. PMID 11716046
7. **Safer JD**, Crawford TM, Fraser LM, Hoang M, Ray S, Chen TC, Persons K, Holick MF. Thyroid hormone action on skin: diverging effects of topical versus intraperitoneal administration. *Thyroid* 2003;13(2):159-165. PMID 12699590
8. Santini F, Ceccarini G, Montanelli L, Rosellini V, Mammoli C, Macchia P, Gatti G, Pucci E, Marsili A, Chopra IJ, Chiovato L, Vitto P, **Safer JD**, Braverman LE, Martino E, Pinchera A. Role for inner ring deiodination preventing transcutaneous passage of thyroxine. *J Clin Endocrinol Metab* 2003;88(6):2825-2830. PMID 12788895
9. **Safer JD**, Crawford TM, Holick MF. A role for thyroid hormone in wound healing through keratin gene expression. *Endocrinology* 2004;145(5):2357-2361. PMID 14736740
10. **Safer JD**, Crawford TM, Holick MF. Topical thyroid hormone accelerates wound healing in mice. *Endocrinology* 2005;146(10):4425-4430. PMID 15976059

**Joshua D. Safer, MD, FACP**

11. Saha AK, Persons K, **Safer JD**, Luo Z, Holick MF, Ruderman NB. AMPK regulation of the growth of cultured human keratinocytes. *Biochem Biophys Res Co* 2006;349(2):519-24. PMID 16949049
12. **Safer JD**, Ray S, Holick MF. A topical PTH/PTHrP receptor antagonist stimulates hair growth in mice. *Endocrinology* 2007;148(3):1167-1170. PMID 17170098
13. **Safer JD**, Persons K, Holick MF. A thyroid hormone deiodinase inhibitor can decrease cutaneous cell proliferation in vitro. *Thyroid* 2009;19(2):181-185. PMID 19191748
14. Ariza MA, Loken WM, Pearce EN, **Safer JD**. Male sex, African-American race/ethnicity, and T3 levels at diagnosis are predictors of weight gain following medication and radioactive iodine treatment for hyperthyroidism. *Endocr Pract* 2010;16(4):609-616. PMID 20350916
15. Abraham TM, de las Morenas A, Lee SL, **Safer JD**. In thyroid fine needle aspiration, use of bedside-prepared slides significantly increased diagnostic adequacy and specimen cellularity relative to solution-based samples. *Thyroid* 2011;21(3):237-242. PMID 21323589
16. Huang MP, Rodgers KA, O'Mara R, Mehta M, Abuzahra HS, Tannenbaum AD, Persons K, Holick MF, **Safer JD**. The thyroid hormone degrading Dio3 is the primary deiodinase active in murine epidermis. *Thyroid* 2011;21(11):1263-1268. PMID 21936673
17. Toraldo G, Bhasin S, Bakhit M, Guo W, Serra C, S, **Safer JD**, Bhawan J, Jasuja R. Topical androgen antagonism promotes cutaneous wound healing without systemic androgen deprivation by blocking beta-catenin nuclear translocation and cross-talk with TGF-beta signaling in keratinocytes. *Wound Repair Regen* 2012;20:61-73. PMID 22276587
- 18\*\*. **Safer JD**, Pearce EN. A simple curriculum content change increased medical student comfort with transgender medicine. *Endocr Pract* 2013;19(4):633-637. PMID 23425656  
- First ever demonstration of the effectiveness of an evidence-based approach to teaching transgender medicine to medical students
- 19\*\*. Thomas DD, **Safer JD**. A simple intervention raised resident-physician willingness to assist transgender patients seeking hormone therapy. *Endocr Pract* 2015;21(10):1134-42. PMID 26151424  
- First ever demonstration of the effectiveness of an evidence-based approach to teaching transgender medicine to physician trainees
20. Mundluru SN, **Safer JD**, Larson, AR. Unforeseen ethical challenges for isotretinoin treatment in transgender patients. *Int J of Womens Dermatol* 2016;2(2):46-48. PMID 28492004
21. Eriksson SES, **Safer JD**. Evidence-based curricular content improves student knowledge and changes attitudes towards transgender medicine. *Endocr Pract* 2016;22(7):837-841. PMID 27042742
22. Chan B, Skocylas R, **Safer JD**. Gaps in transgender medicine content identified among Canadian medical school curricula. *Transgender Health* 2016;1(1):142-150. PMID 29159305
23. Myers SC, **Safer JD**. Increased rates of smoking cessation observed among transgender women receiving hormone treatment. *Endocr Pract* 2017;23(1):32-36. PMID 27682351

**Joshua D. Safer, MD, FACP**

24. Berli J, Knudson G, Fraser L, Tangpricha V, Ettner R, Ettner F, **Safer JD**, Graham j, Monstrey S, Schechter L. Gender confirmation surgery: What surgeons need to know when providing care for transgender individuals. *JAMA Surgery* 2017;152(4):394-400. PMID 28196182
25. Kailas M, Lu HMS, Rothman EF, **Safer JD**. Prevalence and types of gender-affirming surgery among a sample of transgender endocrinology patients prior to state expansion of insurance coverage. *Endocr Pract* 2017;23(7):780-786. PMID 28448757
26. Liang JJ, Gardner IH, Walker JA, **Safer JD**. Observed deficiencies in medical student knowledge of transgender and intersex health. *Endocr Pract* 2017;23(8):897-906. PMID 28534684
27. Park JA, **Safer JD**. Clinical exposure to transgender medicine improves students' preparedness above levels seen with didactic teaching alone: A key addition to the Boston University model for teaching transgender health care. *Transgender Health* 2018;3(1),10-16. PMID 29344576
28. Liang JJ, Jolly D, Chan KJ, **Safer JD**. Testosterone levels achieved by medically treated transgender women in a United States endocrinology clinic cohort. *Endocr Pract* 2018; In Press. PMID 29144822
29. Chan KJ, Jolly D, Liang JJ, Weinand JD, **Safer JD**. Estrogen levels do not rise with testosterone treatment for transgender men. *Endocr Pract* 2018; In Press. PMID

**Case Reports, Reviews, Chapters:****Editorials and Critical Reviews:**

30. **Safer JD**, Colan SD, Fraser LM, Wondisford FE. A pituitary tumor in a patient with thyroid hormone resistance: A diagnostic dilemma. *Thyroid* 2001;11(3):281-291. PMID 11327621
31. **Safer JD**, Hennessey JV, Braverman LE. Substituting brand name levothyroxine preparations with generics would increase treatment cost. *Ann Intern Med* 2005; on-line available at <http://www.annals.org/cgi/eletters/142/11/891#1882>
32. Pietras SM, **Safer JD**. A spurious elevation of both total thyroid hormone and thyroid hormone uptake measurements in the setting of autoantibodies may result in diagnostic confusion: A case report and review of the related literature. *Endocr Pract* 2008;14(6):738-742. PMID 18996795
33. **Safer JD**, Tangpricha V. Out of the Shadows: It is time to mainstream treatment for transgender patients. *Endocr Pract* 2008;14(2):248-50. PMID 18308667
34. Feldman J, **Safer JD**, Hormone therapy in adults: Suggested revisions to the sixth version of the Standards of Care. *Int J Transgenderism* 2009;11(3):146-182.
35. Bhasin S, **Safer JD**, Tangpricha V. The Hormone Foundation's patient guide to the endocrine treatment of transsexual persons. *J Clin Endocrinol Metab* 2009;94(9).
36. **Safer JD**. Thyroid hormone action on skin. *Dermatoendocrinol* 2011;3(3):1-5. PMID 22110782

**Joshua D. Safer, MD, FACP**

37. **Kannan S, Safer JD.** Finding the right balance between resistance & sensitivity -- A case report and brief review of the cardiac manifestations of the syndrome of resistance to thyroid hormone and the implications for treatment. *Endocr Pract* 2012; 18(2):252-255. PMID 22068246
38. **Safer JD.** Thyroid hormone action on skin. *Curr Opin Endocrinol Diabetes Obes* 2012;19(5):388-293. PMID 22914563
39. **Safer JD.** Thyroid hormone and wound healing. *J Thyroid Res* 2013;doi:10.1155/2013/124538. PMID 23577275
40. **Safer JD.** Transgender medical research, provider education, and patient access are overdue. *Endocr Pract* 2013;19(4):575-6. PMID 23337168
41. **Gardner IH, Safer JD.** Progress on the road to better medical care for transgender patients. *Curr Opin Endocrinol Diabetes Obes* 2013;20(6):553-558. PMID 24468757
42. Gitlin SD, Flaherty J, Arrighi J, Swing S, Vasiliadis J, Brater DC, Breida M, Caverzagie K, Kane GC, Nelson Grier C, Parsons P, Smith B, Morrison L, Radwany S, Quill T, Kapur V, Roberts B, Silber M, DiBisceglie A, Fix O, Koteish A, Palumbo P, Trence D, Berkowitz L, Holmboe E, Hood S, Iobst W, Levin S, Yaich S, Foster J, Jackson M, Juvin J, Williams E, Addrizzo-Harris D, Buckley J, Markowitz P, Sessler C, Torrington K, Richter S, Szykowski R, Alguire P, Cooke M, Bolster M, Brown C, Jones T, Marks L, Pardi D, Rose Z, Shah B, Busby-Whitehead J, Granville L, Leipzig R, Collichio F, Raymond M, Von Roenn J, Albertson D, Coyle W, Sedlack R, Abbott B, Fessler H, Balasubramanian A, Danoff A, Gopalakrishnan G, Piquette C, Schulman D, Geraci M, Rockey D, **Safer J**, Armstrong W, Havlicek Jr D, Helmy T, Kolansky D, Patores S, Spevetz A, Biller B, Cantelmi A. The Internal Medicine Subspecialty Milestone Project, a joint initiative of the Accreditation Council for Graduate Medical Education and the American Board of Internal Medicine, in collaboration with the Alliance for Academic Internal Medicine. 2014; online available at <https://www.acgme.org/acgmeweb/Portals/0/PDFs/Milestones/InternalMedicineSubspecialtyMilestones.pdf>
- 43\*\*. **Saraswat A, Weinand JD, Safer JD.** Evidence supporting the biological nature of gender identity. *Endocr Pract* 2015; 21(2):199-204. PMID 25667367  
- Review of the biological nature of transgender identity most referenced by popular media (Google)
- 44\*\*. **Weinand JD, Safer JD.** Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals. *J Clin Transl Endocr* 2015; 2:55-60. PMID 28090436  
- The most comprehensive recent review of the relative safety of transgender hormone therapy
45. **Boh B, Safer JD.** State-of-the-art: Use of hormones in transgender individuals. *Endocrine Society* 2016; online available at <http://dx.doi.org/10.1210/MTP5.9781943550043.ch55>
46. **Safer JD, Coleman E, Hembree, W.** There is reason for optimism: an introduction to the special issue on research needs in transgender health and medicine. *Curr Opin Endocrinol Diabetes Obes* 2016; 23(2):165-167. PMID 26702853

**Joshua D. Safer, MD, FACP**

- 47\*\*. **Safer JD**, Coleman E, Feldman J, Garofalo R, Hembree W, Radix A, Sevelius J. Barriers to healthcare for transgender individuals. *Curr Opin Endocrinol Diabetes Obes* 2016; 23(2):168-171. PMID 26910276  
 - The most current review of barriers to delivery of transgender healthcare in the United States in the medical system, medical curriculum, and medical culture
48. Feldman J, Brown GR, Deutsch MB, Hembree W, Meyer W, Meyer-Bahlburg HFL, Tangpricha V, T'Sjoen G, **Safer JD**. Priorities for transgender medical and healthcare research. *Curr Opin Endocrinol Diabetes Obes* 2016; 23(2):180-187. PMID 26825469
49. Reisner SL, Deutsch MB, Bhasin S, Bockting W, Brown GR, Feldman J, Garofalo R, Kreukels B, Radix A, **Safer JD**, Tangpricha V, T'Sjoen G, Goodman M. Advancing Methods for U.S. Transgender Health Research. *Curr Opin Endocrinol Diabetes Obes* 2016; 23(2):198-207. PMID 26845331
50. **Safer JD**. The large gaps in transgender medical knowledge among providers must be measured and addressed. *Endocr Pract* 2016;22(7):902-903. PMID 27214166
51. Bouman WP, Suess Schwend A, Motmans J, Smiley A, **Safer JD**, Deutsch MB, Adams NJ, Winter S. Language and trans health. *Int J Transgenderism* 2017;18(1):1-6.
52. **Safer JD**. The recognition that gender identity is biological complicates some previously settled clinical decision making. *AACE Clinical Case Rep* 2017;3(3):e289-e290. PMID 27967232
- 53\*\*. Hembree WC, Cohen-Kettenis P, Gooren L, Hannema SE, Meyer WJ, Murad M, Rosenthal S, **Safer JD**, Tangpricha V, T'Sjoen G. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2017; 102(11):1–35. PMID 28945902  
 - The most respected guideline for hormone treatment of transgender individuals
54. **Safer JD**. Transgender patients and health care providers. *Health Affairs* 2017;36(12):2213. PMID 29200359
55. Tangpricha V, Hannema SE, Irwig M, Meyer WJ, **Safer JD**, Hembree WC. 2017 American Association of Clinical Endocrinologists/Endocrine Society update on transgender medicine: case discussions. *Endocr Pract* 2017;23(12):1430-1436. PMID 29320643
56. **Safer JD**. Managing intersex and transgender health across the globe requires more than just understanding the science. *AACE Clinical Case Rep* 2018; In Press. PMID

**Textbook Chapters:**

57. **Safer JD**, Wondisford, FE. 1997 TSH, normal physiology, *Contemporary Endocrinology: Diseases of the Pituitary*, Wierman ME, ed., Humana Press Inc., Totowa, NJ, 283-293
58. **Safer JD**. 2003 Resistance to thyroid hormone, *Contemporary Endocrinology: Diseases of the Thyroid*, 2<sup>nd</sup> Edition, Braverman LE, ed., Humana Press Inc., Totowa, NJ, 199-216

**Joshua D. Safer, MD, FACP**

59. **Safer JD.** 2005 The skin in thyrotoxicosis, *Werner and Ingbar's The Thyroid*, 9<sup>th</sup> Edition, Braverman LE and Utiger RD, eds., Lippincott Williams and Williams, Philadelphia, PA, 553-558
60. **Safer JD.** 2005 The skin and connective tissue in hypothyroidism, *Werner and Ingbar's The Thyroid*, 9<sup>th</sup> Edition, Braverman LE and Utiger RD, eds., Lippincott Williams and Williams, Philadelphia, PA, 769-773
61. **Safer JD, Holick MF.** 2008 Potential therapeutic uses of thyroid hormone, *Thyroid Disorders with Cutaneous Manifestations*, Heymann WR, ed., Springer-Verlag, London, UK, 181-186
62. Leung AM, **Safer JD.** 2012 Thyrotoxicosis of extra thyroid origin, *Werner and Ingbar's The Thyroid*, 10<sup>th</sup> Edition, Braverman LE and Cooper D, eds., Lippincott Williams and Williams, Philadelphia, PA, 429-433
63. Kurani PN, Goldberg LJ, **Safer JD.** 2017 Evaluation and management of hirsutism in postmenopausal women, *Essentials of Menopause Management: A Case-Based Approach*, Pal L and Sayegh RA, eds., Springer, London, UK, 209-221
64. Sloan CA, **Safer JD.** 2017 The high risk client: Comorbid conditions that affect care, *Adult Transgender Care: An Interdisciplinary Approach for Training Mental Health Professionals*, Kauth MR and Shipherd JC, eds., Routledge, Taylor and Francis, London, UK
65. Webb R, **Safer JD.** 2018 Transgender hormonal treatment, *Yen and Jaffe's Reproductive Endocrinology, edition 8*, Strauss JS and Barbieri JL, eds., Elsevier, Maryland Heights, MO, In Press
66. Myers SC, **Safer JD.** 2018 Hormone therapy in transgender adults, *Manual of Endocrinology and Metabolism, 5<sup>th</sup> Edition*, Lavin N, ed., Walters Kluwer, Alphen aan den Rijn, The Netherlands, In Press

**Case Reports:**

67. Koutkia P, **Safer JD.** Adrenal metastasis secondary to papillary thyroid carcinoma. *Thyroid* 2001;11(11):1077-1079. PMID 11762719
68. Choong K, **Safer JD.** Graves disease and gynecomastia in two roommates. *Endocr Pract* 2011;17(4):647-650. PMID 21613048
69. Safer DL, Bullock KD, **Safer JD.** Obsessive-compulsive disorder presenting as gender dysphoria/gender incongruence: a case report and literature review. *AACE Clinical Case Rep* 2016;2:e268–e271.
70. Stevenson MO, Wixon N, **Safer JD.** Scalp Hair Regrowth in Hormone-Treated Transgender Woman. *Transgender Health* 2017;1(1):202-204. PMID 28861534
71. Sullivan CA, Hoffman JD, **Safer JD.** 17- $\beta$ -hydroxysteroid dehydrogenase type 3 deficiency: Identifying a rare cause of 46, XY female phenotype in adulthood. *J Clin Transl Endocr Case Reports* 2018; 7:5-7.

**Joshua D. Safer, MD, FACP**

**Dissemination Through Lay Press and Social Media**

**Mass Audience Programming:**

“Transgender Health AMA” Reddit. July 24, 2017. Expert responses to questions about transgender medicine. [https://www.reddit.com/r/science/comments/6p7uhb/transgender\\_health\\_ama\\_series\\_im\\_joshua\\_safer/](https://www.reddit.com/r/science/comments/6p7uhb/transgender_health_ama_series_im_joshua_safer/) over 150,000 views, over 4200 comments

“Gender Revolution with Katie Couric” National Geographic Channel. Kouric, Katie. February 6, 2017. Extended interview with Katie Couric threaded into a 2-hour television special. Trailer: <https://www.youtube.com/watch?v=y93MsRaC6Zw> broadcast in 143 countries

“Is gender identity biologically hard-wired?” Judd, Jackie. PBS NewsHour. May 13, 2015. Extended interview for Jackie Judd <http://www.pbs.org/newshour/bb/biology-gender-identity-children/> estimated just over 1,000,000 viewers per Nielsen

**Joshua D. Safer, MD, FACP**

<b>Innovation</b>	<b>Significance/impact</b>
<i>Development and leadership of the Transgender Medicine Clinical Center at Boston Medical Center</i>	<ul style="list-style-type: none"> <li>• The Center for Transgender Medicine and Surgery at BMC is the first comprehensive center for transgender medical care in New England</li> <li>• The Center is one of only several such centers in North America that are housed in academic teaching hospitals where care can be integrated</li> <li>• The Center is a model for such care delivery in North America.</li> </ul>
<i>Development and dissemination of the seminal reviews that are most widely cited in the lay press that explain the concept that gender identity is a biological phenomenon (see bibliography section above, e.g. PMID: 25667367).</i>	<ul style="list-style-type: none"> <li>• The concept that gender identity is a biological phenomenon has been a key component of the recent culture change in favor of mainstream medical care for transgender individuals (see media section above)</li> </ul>
<i>Development and dissemination of new and influential curricular content to teach the biology of gender identity in conventional medical education (see curriculum section above)</i>	<p>The teaching of evidence-based approaches to transgender medical care to:</p> <ul style="list-style-type: none"> <li>• Medical students (see bibliography section above, e.g. PMID 23425656 and PMID 27042742)</li> <li>• Physician trainees (see bibliography section above, e.g. PMID 26151424)</li> <li>• Practicing physicians (see invited lectures section above) serves as a crucial component to the gained credence given to care for transgender individuals in conventional medical settings.</li> </ul>
<i>Development and dissemination of seminal reviews supporting the safety of transgender hormone treatment regimens (see invited lectures section above)</i>	<ul style="list-style-type: none"> <li>• Once mainstream medical providers learn of the biology underlying gender identity, their biggest concern is the relative safety of the medical interventions relative to the benefit.</li> <li>• The development and dissemination of the seminal reviews and lectures supporting the safety of current treatment regimens serves as a further crucial component to the culture change among conventional medical providers in favor of routine medical care for transgender individuals</li> </ul>